Tofacitinib Delay May Give FDA Time To Look At New Radiographic Data
This article was originally published in Pharmaceutical Approvals Monthly
FDA has extended the review deadline to look over requested data on tofacitinib, but Pfizer also is interested in turning over an interim analysis of the ORAL Start study, which provides radiographic evidence of tofacitinib’s structural benefit in rheumatoid arthritis, a weak point in the NDA.
You may also be interested in...
FDA’s Arthritis Advisory Committee said May 9 that Pfizer had worded the second-line indication too broadly, and indicated that a 5 mg dose is to be preferred, at least to begin with, due to safety concerns.
The marketability and even the approvability of the first-in-class JAK inhibitor for treatment of rheumatoid arthritis may hinge on whether it can be shown to offer patients a structural benefit. FDA briefing documents for the May 9 advisory committee review show issues with those findings.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.